Condition: Ulcerative Colitis (Disorder) · Sponsor: Showa Inan General Hospital
Eligible patients will be identified in regular clinical practice. After providing thorough explanation and obtaining voluntary written informed consent, the clinical course, adverse events, endoscopic findings, and histopathological changes in biopsy specimens after Etrasimod administration will be prospectively collected and analyzed.
This description comes directly from the study's public registry record.
Norio Saegusa · 81265822121 · ikyoku.tosho@sihp.jp
Always discuss trial participation with your own doctor first.
| Showa Inan General Hospital | Komagane, Nagano, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07243639